Review
Oncology
Anthony J. Murphy, Alex H. Li, Peichao Li, Hong Sun
Summary: Alternative splicing plays a crucial role in diversifying the proteome and has significant implications in cancer development. Recent studies have highlighted the important roles of SR proteins in cancer progression. Understanding the spliceosome and its relationship to cancer has opened up new opportunities for therapeutic interventions based on alternative splicing.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Subhashis Natua, Cheemala Ashok, Sanjeev Shukla
Summary: Maintenance of oxygen homeostasis is crucial for the existence of multicellular organisms, and disruption of this homeostasis can lead to pathological hypoxia in various conditions. Cellular adaptations include changes in gene expression, post-transcriptional modification of gene products, bioenergetics, and metabolism under hypoxic conditions. Hypoxia-induced alternative splicing events are associated with diseases like cancer, cardiovascular diseases, and neurological disorders, offering potential strategies for novel translational diagnosis and therapeutic interventions.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2021)
Review
Cell Biology
Antonio J. Montero-Hidalgo, Jesus M. Perez-Gomez, Antonio J. Martinez-Fuentes, Enrique Gomez-Gomez, Manuel D. Gahete, Juan M. Jimenez-Vacas, Raul M. Luque
Summary: Bladder cancer is the most common malignancy of the urinary tract worldwide. The disease can be treated with surgery, chemotherapy, and immunotherapy, but many patients develop resistance to these treatments and experience aggressive metastasis with poor prognosis. The molecular heterogeneity of bladder cancer is a significant limitation, but the dysregulation of RNA splicing has been identified as a potential target for diagnosis, prognosis, and therapy. Targeting specific splicing factors, mRNA splicing variants, and circular RNAs has shown promising antitumor effects, offering new possibilities for improving the management of this devastating cancer type.
WILEY INTERDISCIPLINARY REVIEWS-RNA
(2023)
Review
Biochemistry & Molecular Biology
Yuanjiao Zhang, Jinjun Qian, Chunyan Gu, Ye Yang
Summary: The study systematically describes the abnormal regulation and functions of alternative splicing in tumors, as well as introduces therapeutic strategies targeting splicing catalysis and regulatory proteins. Further research is needed to fully understand the association between alternative splicing and cancer.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Article
Oncology
Chunyin Wei, Weishun Xie, Xiaoliang Huang, Xianwei Mo, Zujun Liu, Guo Wu, Yongsheng Meng, Franco Jeen, Lianying Ge, Lihua Zhang, Lixian Liao, Jungang Liu, Weizhong Tang
Summary: This study performed genome-wide analysis of AS events and identified differentially expressed AS events in GC, establishing prognostic signatures based on DEAS and discovering a correlation network between DEAS and genes. The results suggest that parental genes before DEAS events play a crucial role in regulating GC-related processes, DEAS based on splicing patterns can stratify patients, and DEAS shows good prognostic performance in patients with GC.
Review
Oncology
Jiawei Ouyang, Yijie Zhang, Fang Xiong, Shanshan Zhang, Zhaojian Gong, Qijia Yan, Yi He, Fang Wei, Wenling Zhang, Ming Zhou, Bo Xiang, Fuyan Wang, Xiaoling Li, Yong Li, Guiyuan Li, Zhaoyang Zeng, Can Guo, Wei Xiong
Summary: This article introduces the definition of alternative splicing in eukaryotes and its importance in cancer development. Alternative splicing is a transcription process that allows coding genes to be translated into multiple proteins with different functions. Alterations in splicing mechanisms may lead to changes in the splicing patterns of cancer-related genes.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Review
Cell Biology
Nan Han, Zhaoqi Liu
Summary: Tumor immunotherapy has made significant progress but still faces challenges. Alternative splicing plays a critical role in expanding cancer-specific antigens and modulating immunogenicity. Organoid technology facilitates the development of splicing-based immunotherapy by preserving individual immune microenvironment and reducing costs.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Review
Biochemistry & Molecular Biology
James D. D. Fackenthal
Summary: Cancer is a leading cause of death worldwide. Alternative mRNA splicing has recently been recognized as a major contributor to cancer initiation and progression. Cancer cells exhibit different distribution of splicing variants compared to non-cancer cells, and they are more sensitive to drugs targeting the splicing regulatory network. Certain recurring splicing variants have been shown to contribute to tumor progression, while some disruption events result from mutations in splicing regulatory sequences or shifts in balance among naturally occurring splicing variants of mRNAs involved in cell cycle progression and apoptosis regulation. This review explores cancer-related alternative splicing events and potential therapies.
Article
Oncology
Jia Liu, Dekang Lv, Xiaobin Wang, Ruicong Wang, Xiaodong Li
Summary: This study systematically analyzed the survival-related AS signal in ovarian serous cystadenocarcinoma and established a new comprehensive prognostic model based on seven AS events. The models were highly efficient in distinguishing patient survival and showed higher prediction ability than mRNA signature, which could be used as potential predictor and therapeutic target for patients with OV.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemical Research Methods
Jiashu Liu, Cui-Xiang Lin, Xiaoqi Zhang, Zongxuan Li, Wenkui Huang, Jin Liu, Yuanfang Guan, Hong-Dong Li
Summary: Alternative splicing (AS), a key pathway for transcriptional regulation, has been shown to be associated with complex diseases. Computational approaches for detecting disease-associated AS events have been developed. This review discusses the metrics used for characterizing AS events quantitatively. It also reviews and discusses three types of methods for detecting disease-associated splicing events: differential splicing analysis, aberrant splicing detection, and splicing-related network analysis. Additionally, methods for detecting genetic variants that potentially regulate splicing are described. Experimental comparisons are conducted to illustrate the performance of each method. The limitations of these methods are discussed, as well as potential ways to address them. This review aims to provide a systematic understanding of computational approaches for analyzing disease-associated splicing.
BRIEFINGS IN BIOINFORMATICS
(2023)
Review
Oncology
Sunkyung Choi, Namjoon Cho, Eun-Mi Kim, Kee K. Kim
Summary: Alternative pre-mRNA splicing plays a critical role in generating multiple mRNA and increasing protein diversity. Specific splicing isoforms have been found to be important in cellular processes, particularly in regulating cell numbers. Abnormal expression of splicing isoforms and factors, as well as disruptions in splicing caused by genetic mutations, are implicated in cancer development and progression. Alternative splicing has potential as a therapeutic target for cancer.
CANCER CELL INTERNATIONAL
(2023)
Review
Oncology
Antoine Bernard, Romain Boidot, Frederique Vegran
Summary: This article presents the role and mechanism of alternative splicing in cancer cells and immune cells. Alternative splicing is an important mechanism that can generate multiple proteins from a single gene. In normal cells, alternative splicing is involved in the regulation of cellular behavior. However, in cancer, alternative splicing is dysregulated and contributes to the characteristics of tumor cells.
Article
Multidisciplinary Sciences
Yang Pan, John W. Phillips, Beatrice D. Zhang, Miyako Noguchi, Eric Kutschera, Jami McLaughlin, Pavlo A. Nesterenko, Zhiyuan Mao, Nathanael J. Bangayan, Robert Wang, Wendy Tran, Harry T. Yang, Yuanyuan Wang, Yang Xu, Matthew B. Obusan, Donghui Cheng, Alex H. Lee, Kathryn E. Kadash-Edmondson, Ameya Champhekar, Cristina Puig-Saus, Antoni Ribas, Robert M. Prins, Christopher S. Seet, Gay M. Crooks, Owen N. Witte, Yi Xing
Summary: This study describes a computational platform called IRIS that can discover tumor antigens derived from alternative splicing, providing potential targets for TCR and CAR-T immunotherapies. Through the analysis of transcriptomics and immuno-peptidomics data, the study demonstrates that the predicted targets by IRIS can bind with HLA molecules. The study illustrates the contribution of alternative splicing to the repertoire of tumor antigens and demonstrates the utility of IRIS in discovering AS-derived antigens and expanding cancer immunotherapies.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Review
Oncology
Yunze Liu, Xin Liu, Changwei Lin, Xianhong Jia, Hongmei Zhu, Jun Song, Yi Zhang
Summary: AS and ncRNAs play crucial roles in cancer by influencing the development of various diseases, especially in different aspects of cancer progression. Acting as regulatory molecules, ncRNAs can affect cell signaling pathways by influencing AS, thus impacting cancer progression.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Wei-zhao Peng, Jin Zhao, Xin Liu, Chao-feng Li, Shuang Si, Ren Ma
Summary: The study shows that overexpression of hnRNPA2B1 in GC is associated with poor survival and is required for maintaining a malignant phenotype by promoting cell proliferation, inhibiting cell apoptosis, and increasing cell metastasis. Mechanistically, hnRNPA2B1 is co-expressed with several core spliceosome components and controls alternative splicing of the anti-apoptotic factor BIRC5. The BIRC5 isoform 202 plays an oncogenic role in GC cells, and overexpression of the BIRC5-202 transcript partially restores cisplatin resistance decreased by downregulation of hnRNPA2B1.
CANCER CELL INTERNATIONAL
(2021)
Article
Chemistry, Medicinal
Martin Perez-Santos, Maricruz Anaya-Ruiz, Irma Herrera-Camacho, Nora Hilda Rosas-Murrieta, Lourdes Millan-Perez Pena
EXPERT OPINION ON THERAPEUTIC PATENTS
(2020)
Article
Chemistry, Medicinal
Lourdes Millan-Perez Pena, Perez-Santos Martin, Irma Herrera-Camacho, Cindy Bandala, Maricruz Anaya-Ruiz
EXPERT OPINION ON THERAPEUTIC PATENTS
(2020)
Article
Biochemistry & Molecular Biology
Emmanuel Rojas-Morales, Gerardo Santos-Lopez, Samuel Hernandez-Cabanas, Raul Arcega-Revilla, Nora Rosas-Murrieta, Carolina Jasso-Miranda, Elie Girgis El-Kassis, Julio Reyes-Leyva, Virginia Sedeno-Monge
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Review
Chemistry, Medicinal
Jorge Cebada, Martin Perez-Santos, Cindy Bandala, Eleazar Lara-Padilla, Irma Herrera-Camacho, Nora Hilda Rosas-Murrieta, Lourdes Millan-Perez Pena, Eduardo Monjaraz, Amira Flores, Maricruz Anaya-Ruiz
Summary: OX40 is an immune checkpoint associated with a good prognosis in cancer, making it a relevant target for new immunotherapy development. The patent literature analysis revealed an increasing trend in the development of OX40 agonists in cancer, particularly in the years 2018 and 2019. Major pharmaceutical companies such as AstraZeneca, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, and Roche have developed a majority of OX40 agonists in clinical trials.
EXPERT OPINION ON THERAPEUTIC PATENTS
(2021)
Article
Biotechnology & Applied Microbiology
Ileana Conde-Rodriguez, Guadalupe Delgado-Lopez, Erick Armenta-Castro, Ivonne Ramirez-Diaz, Maricruz Anaya-Ruiz, Claudia T. Gutierrez-Quiroz, Juan Carlos Flores-Alonso, Salvador Reyes-Salinas, Victor J. Vazquez-Zamora, Francisco J. Ceja-Utrera, Aurelio Lopez-Colombo, Julio Reyes-Leyva, Gustavo Lopez-Lopez, Veronica Vallejo-Ruiz
BIOMED RESEARCH INTERNATIONAL
(2020)
Article
Biochemistry & Molecular Biology
Veronica Rodriguez-Lopez, Cesar Millan-Pacheco, Judith Gonzalez-Christen, Maricruz Anaya-Ruiz, Omar Aristeo Pena-Moran
Summary: The study analyzed the mechanisms of action of two compounds isolated from Bursera fagaroides var. fagaroides, finding that they exhibited activity by inhibiting microtubule polymerization but not topoisomerase II activity. Additionally, modification of rigid and semiflexible residues in docking methods could provide better in vitro correlation.
Article
Multidisciplinary Sciences
Alan Rodriguez-Enriquez, Irma Herrera-Camacho, Lourdes Millan-Perez-Pena, Julio Reyes-Leyva, Gerardo Santos-Lopez, Jose Francisco Rivera-Benitez, Nora Hilda Rosas-Murrieta
Summary: This study presents a predicted 3D model of the PEDV M protein and identifies multiple linear and discontinuous B-cell epitopes, as well as weak and strong binding T-cell epitopes. Conservation of these epitopes is observed among different PEDV strains, suggesting that the M protein could be a potential candidate for developing new treatments or strategies against viral diseases.
Article
Pharmacology & Pharmacy
Maricruz Anaya-Ruiz, Martin Perez-Santos
Summary: Inhibition of the PD-1/PD-L1 pathway is a target for new therapies, with a US10710986 patent describing a small molecule targeting PDL-1/PD-1 interactions for antitumor activity against colorectal cancer. However, there are currently no reports on the efficacy of this small molecule in other types of cancer, and clinical trials are needed to evaluate its safety, toxicity, and efficacy.
PHARMACEUTICAL PATENT ANALYST
(2021)
Editorial Material
Pharmacology & Pharmacy
Maricruz Anaya-Ruiz, Martin Perez-Santos
Summary: Adapalene shows potential as a repurposing drug for the treatment of melanoma, although no clinical evidence on efficacy and efficiency has been demonstrated.
PHARMACEUTICAL PATENT ANALYST
(2022)
Review
Pharmacology & Pharmacy
Martin Perez-Santos, Maricruz Anaya-Ruiz, Luis Villafana-Diaz, Gabriela Sanchez Esgua
Summary: This article discusses the development strategy of LAG-3 inhibitors and their related clinical trials and patents. The future research challenge is the design and development of peptides and small molecules that can inhibit the function of LAG-3.
EXPERT OPINION ON DRUG DISCOVERY
(2022)
Article
Virology
Francisca Sosa-Jurado, Roxana Palencia-Lara, Cinthia Xicotencatl-Grijalva, Maribel Bernal-Soto, Alvaro Montiel-Jarquin, Yolanda Ibarra-Pichardo, Nora Hilda Rosas-Murrieta, Rosalia Lira, Paulina Cortes-Hernandez, Gerardo Santos-Lopez
Summary: To reduce the risk of virus transmission through blood transfusion, individual donor nucleic acid testing (ID-NAT) has been used in Puebla, Mexico. The data of 106,125 blood donors were analyzed to calculate the residual risk (RR) values for different viruses. ID-NAT has successfully increased the safety of blood reserves for HIV and HCV, but more research is needed to determine why the residual risk of HBV did not decrease as much. Therefore, ID-NAT is an important complementary tool that should be implemented in blood donor screening.
Article
Pharmacology & Pharmacy
Nemesio Villa-Ruano, Maricruz Anaya-Ruiz, Luis Villafana-Diaz, Diana Barron-Villaverde, Martin Perez-Santos
Summary: Research shows that mito-Atovaquone can be used to treat various types of cancer, including pancreatic cancer, lung cancer, and brain cancer. The repurposing of this approved drug strategy saves time and investment.
PHARMACEUTICAL PATENT ANALYST
(2023)
Article
Agronomy
Carlos Francisco Varapizuela-Sanchez, Marco Antonio Sanchez-Medina, Maria del Socorro Pina-Canseco, Nora Hilda Rosas-Murrieta, Alma Dolores Perez-Santiago, Ivan Antonio Garcia-Montalvo
Summary: The glyoxalase system is important in plant responses to various stresses. This study evaluated the activity of GLX-I enzyme in maize coleoptiles in response to Aspergillus flavus infection, and found increased enzyme activity and gene expression after infection.
REVISTA DE LA FACULTAD DE AGRONOMIA DE LA UNIVERSIDAD DEL ZULIA
(2022)
Article
Pharmacology & Pharmacy
Martin Perez-Santos, Maricruz Anaya-Ruiz, Gabriela Sanchez-Esgua, Luis Villafana-Diaz, Diana Barron-Villaverde
Summary: The patent describes a bispecific antibody that targets PD-L1/ICOS, showing anti-tumor efficacy in the CT26 model by depleting T-Reg cells and improving the CD8(+) T cells: T-Reg ratio in the tumor microenvironment. However, there are currently no clinical trial reports, and it remains to be seen if this antibody can outperform combination therapy in cancer treatment.
PHARMACEUTICAL PATENT ANALYST
(2021)